Benzinga · Aug 6, 2026
TD Cowen Maintains Buy on Mirum Pharmaceuticals, Lowers Price Target to $140
TD Cowen analyst Joseph Thome maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and lowers the price target from $145 to $140.
MI
NASDAQ · MIRM
Mirum Pharmaceuticals, Inc.
Healthcare · Biotechnology
$96.31
Down-$0.76 (-0.78%)
Updated Aug 22, 2026, 6:01 AM
SID Score
5.1/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 3.25B
- P/E ratio
- -80.38
- Dividend yield
- 0.00%
- 52-week range
- $84.33 – $130.00
- Volume
- 731.68K
- Avg. volume
- 656.21K
Price performance
MIRM price history
1M range · 21 trading sessions · Daily adjusted prices
MIRM closed at $96.31 after 21 trading sessions, down 14.79% for the selected period.
- Last close
- $96.31
- Period change
- -14.79%
- Period low
- $94.12
- Period high
- $114.20
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | $97.65 | $97.89 | $95.24 | $96.31 | 731.68K |
| Aug 20, 2026 | $100.73 | $101.96 | $96.98 | $97.07 | 352.68K |
| Aug 19, 2026 | $102.50 | $104.66 | $101.54 | $102.24 | 556.27K |
| Aug 18, 2026 | $99.50 | $101.26 | $99.00 | $100.87 | 518.11K |
| Aug 17, 2026 | $99.93 | $101.43 | $99.23 | $99.83 | 407.63K |
| Aug 14, 2026 | $98.03 | $101.31 | $96.73 | $100.64 | 503.79K |
| Aug 13, 2026 | $99.23 | $100.48 | $98.50 | $98.77 | 734.95K |
| Aug 12, 2026 | $98.30 | $100.37 | $98.30 | $98.97 | 649.57K |
| Aug 11, 2026 | $98.58 | $101.02 | $97.51 | $98.23 | 579.02K |
| Aug 10, 2026 | $99.58 | $100.57 | $97.41 | $98.70 | 867.97K |
| Aug 7, 2026 | $94.95 | $101.64 | $94.25 | $100.65 | 850.71K |
| Aug 6, 2026 | $90.25 | $97.00 | $88.8801 | $94.115 | 2.97M |
| Aug 5, 2026 | $105.93 | $107.00 | $104.16 | $105.79 | 882.29K |
| Aug 4, 2026 | $105.08 | $106.99 | $103.315 | $104.33 | 591.58K |
| Aug 3, 2026 | $105.29 | $106.25 | $102.78 | $104.59 | 500.28K |
| Jul 31, 2026 | $113.25 | $113.46 | $105.70 | $105.95 | 578.74K |
| Jul 30, 2026 | $108.04 | $112.81 | $106.00 | $112.59 | 575.88K |
| Jul 29, 2026 | $112.03 | $112.40 | $106.98 | $107.57 | 682.49K |
| Jul 28, 2026 | $114.05 | $115.92 | $110.89 | $112.23 | 437.94K |
| Jul 27, 2026 | $115.15 | $116.39 | $113.465 | $114.20 | 431.34K |
| Jul 24, 2026 | $114.92 | $115.5904 | $111.57 | $113.03 | 516.94K |
Latest MIRM news
The latest Smart Investors Daily articles mentioning MIRM.
Stock researchCompany · Overview
MIRM research
Overview
Company profile and research snapshot.
Company profile
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $98.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 6, 2026 | Citizens | Market Outperform | — |
| Aug 6, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 6, 2026 | TD Cowen | Buy | — |
| Aug 6, 2026 | RBC Capital | Outperform | — |
| Jul 7, 2026 | RBC Capital | Outperform | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 6, 2026
RBC Capital Maintains Outperform on Mirum Pharmaceuticals, Lowers Price Target to $135
RBC Capital analyst Lisa Walter maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Outperform and lowers the price target from $148 to $135.
Benzinga · Aug 6, 2026
Citizens Maintains Market Outperform on Mirum Pharmaceuticals, Lowers Price Target to $137
Citizens analyst Jonathan Wolleben maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Market Outperform and lowers the price target from $146 to $137.
Benzinga · Aug 6, 2026
HC Wainwright & Co. Maintains Buy on Mirum Pharmaceuticals, Lowers Price Target to $140
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and lowers the price target from $185 to $140.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
